Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELAVL1 | Q15717 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22130638 | 0.76 | MEN1 (0.30) | MEN1TSHRKMT2A | |
| SCHEMBL22130643 | 0.71 | — | — | |
| SCHEMBL22130701 | 0.67 | ELAVL1 (0.38) | ELAVL1 | |
| SCHEMBL22130658 | 0.67 | ELAVL1 (0.59) | ELAVL1 | |
| SCHEMBL17322918 | 0.57 | ELANE (0.45) | MEN1TSHRKMT2AALDH1A1HSD17B10 | |
| SCHEMBL22130656 | 0.57 | ELAVL1 (0.49) | ELAVL1MEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL21888965 | 0.53 | MEN1 (0.37) | MEN1TSHRKMT2A | |
| SCHEMBL21888987 | 0.52 | MEN1 (0.33) | MEN1TSHRKMT2A | |
| SCHEMBL22802479 | 0.52 | ALDH1A1 (0.37) | MEN1TSHRKMT2AALDH1A1HSD17B10 | |
| SCHEMBL8733374 | 0.51 | IDO1 (0.33) | MEN1KMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689342-B2 | Aza-tanshinone derivatives, process for their preparation and their use in therapy | UNIVERSITA' DEGLI STUDI DI TRENTO (IT) | 2020-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689342-B2 | Aza-tanshinone derivatives, process for their preparation and their use in therapy | AZI2, TPMT, TYMS | ELAVL1 2765/4885HIF1A 513/4885MEN1 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.